With the introduction of new expensive medicines, traditional pricing schemes based on constructs such as price per pill/vial have been challenged. Potential innovative schemes could be either financial-based or performance-based. Within financial-based schemes the use of price discrimination is an emerging option, which we explore in this assessment.
Two-part Pricing for Patent-protected Medicines Poster presented at ISPOR International Meeting in Philadelphia, May 16-20, 2015 Many new medicines are targeting small patient populations. In order to recoup R&D costs, the medicines are highly priced. A dilemma is that the price per patient (or pill or vial) can be seen as blocking access. As the … Continued
Flexible Pricing Mechanisms: Are Payer and Manufacturer Ready? Presentation at the European Pharmaceutical Pricing and Reimbursement Meeting in London, October 6, 2015 There is major frustration on current drug pricing approaches from all stakeholders. The issues are primarily related to early access, value-for-money, affordability and equity. Historically, pricing has been based on uniform pricing schemes, … Continued
Market Access Challenges for Innovative Cancer Treatments in the Nordic Region Reproduced from IMS’ publication: “Pharma Pricing and Reimbursement” (PPR), January 2014 At SMI’s European Pharmaceutical Pricing and Reimbursement Conference in London, in October 2013, Peter Hertzman offered his perspective on the challenges faced by manufacturers attempting to achieve access to new, innovative oncology products … Continued